UNSPSC 51171836: Cilansetron

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C20H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2J6DQ1U5B5, chemically known as 4h-pyrido(3,2,1-jk)carbazol-11(8h)-one, 5,6,9,10-tetrahydro-10-((2-methyl-1h-imidazol-1-yl)methyl)-, (r)- but generally known as cilansetron, which bears US NIH Compound Identifier 65939. European Medicines Agency schedules Cilansetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06263MIG.

UNSPSC 51171836 Cilansetron is a Commodity code for a specific antiemetic pharmaceutical, but the recent state and local opportunities tagged under it reflect broader drug testing and pharmaceutical supply sourcing work rather than procurement of this compound specifically. State and local governments purchasing under this code area engage in offender drug screening programs, pharmacy benefit management initiatives, and multi-source generic pharmaceutical supply contracts. The issuing bodies are typically corrections departments, health and human services agencies, and cooperative purchasing alliances representing multiple state and local jurisdictions. Work solicited includes specimen collection and laboratory drug testing services (with immunoassay screening and confirmation protocols), information gathering on direct-to-manufacturer pharmaceutical contracting models, and bulk supply agreements for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to state and local health facilities.

Recent opportunities span Texas and Minnesota, with activity concentrated in larger state health systems and multi-jurisdictional cooperative purchasing vehicles. Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services covering two sites in Plano and McKinney with approximately 25,031 annual tests, an estimated contract value of $600,000, a two-year term commencing September 1, 2026, and proposals due July 23, 2026. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to supply state and local government facilities across participating states including Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026.